2 results match your criteria: "University of St Andrewsgrid.11914.3c[Affiliation]"
Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.
Clin Microbiol Rev
September 2022
FIND, the Global Alliance for Diagnostics, Geneva, Switzerland.
Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a global public health threat. A significant challenge for TB control efforts has been the monitoring of TB therapy and determination of TB treatment success. Current recommendations for TB treatment monitoring rely on sputum and culture conversion, which have low sensitivity and long turnaround times, present biohazard risk, and are prone to contamination, undermining their usefulness as clinical treatment monitoring tools and for drug development.
View Article and Find Full Text PDFHigh Mycobacterium tuberculosis Bacillary Loads Detected by Tuberculosis Molecular Bacterial Load Assay in Patient Stool: a Potential Alternative for Nonsputum Diagnosis and Treatment Response Monitoring of Tuberculosis.
Microbiol Spectr
February 2022
Division of Infection and Global Health, School of Medicine, University of St Andrewsgrid.11914.3c, Scotland, United Kingdom.
Article Synopsis
- Not all patients with tuberculosis (TB) produce sputum, necessitating alternative diagnostic methods like the TB molecular bacterial load assay (TB-MBLA) for detecting M. tuberculosis in stool samples.
- In a study of 100 adults, TB-MBLA successfully detected TB in 57 stool samples, showing higher sensitivity (80%) compared to traditional methods such as smear microscopy and MGIT culture.
- This research suggests that stool could be a viable sample type for TB diagnosis, especially since a significant number of TB patients, including those co-infected with HIV, may not produce sputum.